Scrip    Clinica    Scrip Regulatory Affairs    Scrip Clinical Research    AnimalPharm   
Email ID
Password
Forgotten your password?
Sign me in automatically next time
Home
Therapy Sector
Generics
Business
Policy & Regulation
Research & Development
International
Deals
|
M&A
|
Financials
|
Strategy
|
Lifecycle Management
|
Legal
|
Forest pays $75 million up front for US rights to Almirall LABA
21 December 2009
Eleanor Malone

eleanor.malone@informa.com

Forest Laboratories has agreed to pay $75 million up front for US rights to a long-acting beta-agonist in Phase II clinical development for bronchoconstriction in asthmatic patients by Almirall.

The two companies will co-develop LAS100977, a once-daily inhaled treatment candidate, in combination...



Please Login to read the full article.
 
Not a subscriber? Subscribe to Scrip Request a FREE Trial
RELATED CONTENT
NEWS Scrip News Other Informa News
ANALYSIS Scrip Analysis Other Informa Analysis
COMMENT Scrip Comment Other Informa Comment
FEATURES Other Informa Features
EVENTS
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
26 March 2012
Copenhagen, Denmark
JOB OF THE WEEK Promote your vacancy here
© 2012 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36
Home
Therapy Sector
Generics
Business
Policy & Regulation
Research & Development
International
Terms & Conditions
Privacy Policy
Sitemap
About Us
Advertise
Subscribe
Scrip
Clinica
Scrip Regulatory Affairs
Scrip Clinical Research
Animal Pharm